argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company, will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and second quarter business update.

The webcast will be accessible through the Investors section of the argenx website at argenx.com/investors, with a replay available for approximately one year. The company has provided international dial-in numbers and the access code 3810049 for participants, who are advised to dial in 15 minutes before the call.

News Market Reaction

+0.73%

1 alert

+0.73% News Effect

On the day this news was published, ARGX gained 0.73%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

July 24, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                1 888 415 4250
Japan                        81 3 4578 9081
Switzerland                41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

FAQ

When will argenx (ARGX) report its half year 2025 financial results?

argenx will report its half year 2025 financial results on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET).

How can investors access argenx's (ARGX) half year 2025 earnings call?

Investors can access the call through the webcast on argenx.com/investors or by dialing in using country-specific numbers with access code 3810049.

Will argenx's (ARGX) earnings call webcast be available for replay?

Yes, the webcast replay will be available on the argenx website for approximately one year following the presentation.

What is the access code for argenx's (ARGX) half year 2025 earnings call?

The access code for the earnings call is 3810049. Participants should dial in 15 minutes prior to the live call.